登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 15 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 15
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心首都医科大学附属北京地坛医院Beijing Ditan Hospital, Capital Medical University北京医院页面
- 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
- 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
- 研究中心蚌埠医学院第一附属医院First Affiliated Hospital of Bengbu Medical University蚌埠医院页面
- 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
- 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
- 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
- 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
- 研究中心福建医科大学孟超肝胆医院Mengchao Hepatobiliary Hospital of Fujian Medical University福州医院页面
- 研究中心南方医科大学南方医院Nanfang Hospital广州医院页面
- 研究中心南京天印山医院Nanjing Tianyinshan Hospital南京医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07547553,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Participants with advanced or unresectable HCC confirmed by pathological histology or diagnosed in accordance with the clinical criteria specified in the National Health Commission guidelines, with the following additional requirements:
入选标准第 3 条
Tumor tissue IHC testing for FGF19 was positive (confirmed by central laboratory);
入选标准第 5 条
Child-Pugh class A or class B (Child-Pugh score ≤7) ;
入选标准第 6 条
Participated in another clinical trial of investigational drugs or investigational medical devices within 28 days prior to the first dose; or received anticancer treatment within the past 4 weeks before the first dose, or within five half-lives of the drug (whichever is shorter), including but not limited to chemotherapy, radiotherapy (allowing palliative radiotherapy completed at least two weeks prior to investigational product administration), targeted therapy, immunotherapy, or endocrine therapy; or received traditional Chinese medicine with anticancer indications within one week before the first dose.
排除标准第 1 条
The previous antitumor treatment-related toxicity has not yet recovered to ≤ grade 1 or baseline level
排除标准第 2 条
Previously received FGFR inhibitors, including FGFR4 inhibitors and pan-FGFR inhibitors.
排除标准第 3 条
Undergone major surgery (except biopsy) within 4 weeks prior to the first study dose of the investigational product, or surgical wounds not fully healed.
排除标准第 4 条
Bile acid-modulating medications that cannot be discontinued within 3 days prior to the first dose or within 5 half-lives of the drug (whichever is longer).
排除标准第 15 条
ECOG score 0 or 1
入选标准第 8 条
Have at least one measurable lesion according to RECIST v1.1.
入选标准第 9 条
Participants with a known history of other malignancies within 5 years prior to enrollment.
排除标准第 7 条
History of human immunodeficiency virus (HIV) infection, or active infection requiring systemic treatment for more than 7 consecutive days within 14 days prior to the first dose administration.
排除标准第 12 条
Co-infection with HBV and HCV
排除标准第 13 条
Participants (including partners of the male participants) are willing to use effective contraception from the screening period until 6 months after the last investigational product administration.
入选标准第 14 条
Pregnant or lactating females, or those with a positive blood pregnancy test.
排除标准第 17 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07547553,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntary participation in a clinical trial and signed informed consent. Ages 18 to 75 years (inclusive of the boundaries), male or female. Participants with advanced or unresectable HCC confirmed by pathological histology or diagnosed in accordance with the clinical criteria specified in the National Health Commission guidelines, with the following additional requirements: Participants with HCC who have experienced progressive disease after prio systemic therapy; Tumor tissue IHC testing for FGF19 was positive (confirmed by central laboratory); Child-Pugh class A or class B (Child-Pugh score ≤7) ; Barcelona Clinic Liver Cancer (BCLC) stage B or C ECOG score 0 or 1 Have at least one measurable lesion according to RECIST v1.1. Life expectancy ≥ 12 weeks. Adequate organ and bone marrow function. Participants with HCV infection, whose HCV-RNA levels are above the lower limit of detection at the study site, are eligible if antiviral therapy is initiated prior to the first dose administration. Participants with hepatitis B virus (HBV) infection must have HBV DNA < 104 cps/mL or 2,000 IU/mL. Participants (including partners of the male participants) are willing to use effective contraception from the screening period until 6 months after the last investigational product administration.排除标准:Exclusion Criteria:
Participated in another clinical trial of investigational drugs or investigational medical devices within 28 days prior to the first dose; or received anticancer treatment within the past 4 weeks before the first dose, or within five half-lives of the drug (whichever is shorter), including but not limited to chemotherapy, radiotherapy (allowing palliative radiotherapy completed at least two weeks prior to investigational product administration), targeted therapy, immunotherapy, or endocrine therapy; or received traditional Chinese medicine with anticancer indications within one week before the first dose. The previous antitumor treatment-related toxicity has not yet recovered to ≤ grade 1 or baseline level Previously received FGFR inhibitors, including FGFR4 inhibitors and pan-FGFR inhibitors. Undergone major surgery (except biopsy) within 4 weeks prior to the first study dose of the investigational product, or surgical wounds not fully healed. Presence of moderate to large pleural or ascitic effusion accompanied by clinical symptoms, uncontrolled, or requiring repeated drainage. Participants with active or a history of autoimmune diseases that are likely to recur (including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disorders, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or participants at high risk (e.g., participants who have undergone organ transplantation and require immunosuppressive therapy). Participants with a known history of other malignancies within 5 years prior to enrollment. Leptomeningeal (meningeal) metastases, active brain metastases Participants with known active tuberculosis or suspected active tuberculosis, or participants with active pneumonia requiring treatment. History of clinically significant cardiovascular and cerebrovascular diseases. Systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose. History of human immunodeficiency virus (HIV) infection, or active infection requiring systemic treatment for more than 7 consecutive days within 14 days prior to the first dose administration. Co-infection with HBV and HCV Blood transfusion, treatment with granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, thrombopoietin, or erythropoietin initiated within 2 weeks prior to the first dose. Bile acid-modulating medications that cannot be discontinued within 3 days prior to the first dose or within 5 half-lives of the drug (whichever is longer). History of severe allergic reactions to other therapeutic antibody drugs; or known allergy to multiple substances or suffering from severe allergic diseases. Pregnant or lactating females, or those with a positive blood pregnancy test. Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities that, in the investigator's judgment, may increase the risk associated with study participation or may interfere with the interpretation of study results, or any other situation considered unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT07547553, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07547553,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。